NCT03704740View on ClinicalTrials.gov

Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months

PHASE3CompletedINTERVENTIONAL
Enrollment

676

Participants

Timeline

Start Date

October 25, 2018

Primary Completion Date

July 12, 2019

Study Completion Date

July 12, 2019

Conditions
Influenza
Interventions
BIOLOGICAL

NBP607-QIV

Purified inactivated influenza virus surface antigens of four strains (quadrivalent)

BIOLOGICAL

Agrippal

Influenza virus surface antigens of three strains (trivalent)

Trial Locations (1)

13494

SK Bioscience, Gyeonggi-do

All Listed Sponsors
lead

SK Bioscience Co., Ltd.

INDUSTRY

NCT03704740 - Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months | Biotech Hunter | Biotech Hunter